a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram
Kaplan-Meier curve of median progression-free survival (PFS) and... | Download Scientific Diagram
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH.... EHA Library. Harrison C. Jun 9 2021; 324611
Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram
Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram
JCM | Free Full-Text | A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation | HTML
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
NEJM on Twitter: "KEYNOTE-836: In advanced cervical cancer, median PFS was 10.4 months with pembrolizumab and 6 months with placebo. Overall survival at 2 years was 50.4% and 40.4%, respectively. #ESMO21 https://t.co/sZd6SFiGKd
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Kaplan-Meier curves of progression-free survival (PFS) and overall... | Download Scientific Diagram
Median progression-free survival (PFS), duration of response (DOR), and... | Download Scientific Diagram
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
Diagnostics | Free Full-Text | Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
A) Overall survival (OS) and (B) progression-free survival (PFS).... | Download Scientific Diagram
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates | Journal for ImmunoTherapy of Cancer
REVEL Trial Progression-Free Survival for mNSCLC | CYRAMZA® (ramucirumab)
Progression-Free Survival (PFS) | REVLIMID® (lenalidomide) + rituximab
Progression-free survival (PFS) and overall survival (OS) time. Median... | Download Scientific Diagram
